Literature DB >> 30927190

Prevention of complications from use of conventional immunosuppressants: a critical review.

Claudio Ponticelli1,2, Richard J Glassock3.   

Abstract

Synthetic immunosuppressive drugs are largely used in immune-related renal diseases and in kidney transplantation. Most of these drugs have a low therapeutic index (the ratio that compares the blood concentration at which a drug becomes toxic and the concentration at which the drug is effective), which means that the drug should be dosed carefully and the patient monitored frequently. In this review, we consider the categories of synthetic immunosuppressive agents more frequently and conventionally used in clinical nephrology: glucocorticoids, Aalkylating agents (cyclophosphamide, chlorambucil), purine synthesis inhibitors (azathioprine, mycophenolate salts) and calcineurin inhibitors (cyclosporine, tacrolimus). For each category the possible side effects will be reviewed, the general and specific measures to prevent or treat the adverse events will be suggested, and the more common mistakes that may increase the risk of toxicity will be described. However, the efficacy and safety of immunosuppressive agents depend not only on the pharmacologic characteristics of single drugs but can be influenced also by the clinical condition and genetic characteristics of the patient, by the typology and severity of the underlying disease and by the interaction with other concomitantly used drugs.

Entities:  

Keywords:  Calcineurin inhibitors; Cyclophosphamide; Glucocorticoids; Immunosuppression; Mycophenolic acid

Mesh:

Substances:

Year:  2019        PMID: 30927190     DOI: 10.1007/s40620-019-00602-5

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   4.393


  149 in total

1.  Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection.

Authors:  Abdelhamid Liacini; Mark E Seamone; Daniel A Muruve; Lee Anne Tibbles
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

Review 2.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

3.  Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil.

Authors:  Basil Hantash; David Fiorentino
Journal:  Arch Dermatol       Date:  2006-01

Review 4.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 5.  Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis.

Authors:  Leonie H A Broersen; Alberto M Pereira; Jens Otto L Jørgensen; Olaf M Dekkers
Journal:  J Clin Endocrinol Metab       Date:  2015-04-06       Impact factor: 5.958

6.  Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.

Authors:  W R Connell; M A Kamm; J K Ritchie; J E Lennard-Jones
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

7.  Risk factors for BK virus infection in the era of therapeutic drug monitoring.

Authors:  Claire Borni-Duval; Sophie Caillard; Jérôme Olagne; Peggy Perrin; Laura Braun-Parvez; Françoise Heibel; Bruno Moulin
Journal:  Transplantation       Date:  2013-06-27       Impact factor: 4.939

Review 8.  Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Daping Zhang; Diana S-L Chow
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

9.  Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients.

Authors:  Erin L Ohmann; Gilbert J Burckart; Maria M Brooks; Yan Chen; Vera Pravica; Diana M Girnita; Adriana Zeevi; Steven A Webber
Journal:  J Heart Lung Transplant       Date:  2010-01-12       Impact factor: 10.247

10.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Authors:  Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Isenberg; David Jayne; Lei-Shi Li; Eduardo Mysler; Jorge Sánchez-Guerrero; Neil Solomons; David Wofsy
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121

View more
  20 in total

1.  Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.

Authors:  Feng Ma; Xiaoxia Yang; Meilan Zhou; Ming Bai; Lijuan Zhao; Li Li; Ruijuan Dong; Chunmei Liu; Rong Li; Shiren Sun
Journal:  J Nephrol       Date:  2020-05-23       Impact factor: 3.902

Review 2.  Renal sarcoidosis.

Authors:  Marta Calatroni; Gabriella Moroni; Francesco Reggiani; Claudio Ponticelli
Journal:  J Nephrol       Date:  2022-06-27       Impact factor: 4.393

3.  Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement.

Authors:  Bogdan Obrișcă; Alexandra Vornicu; Roxana Jurubiță; Camelia Achim; Raluca Bobeică; Andreea Andronesi; Bogdan Sorohan; Vlad Herlea; Alexandru Procop; Constantin Dina; Gener Ismail
Journal:  Clin Rheumatol       Date:  2021-02-17       Impact factor: 2.980

4.  Local and Systemic Effects of Cyclosporine A on the Severity of Gingival Overgrowth in Post-Transplant Renal Patients.

Authors:  Samia Aboujaoude; Georges Aoun; Zeina Majzoub
Journal:  Mater Sociomed       Date:  2021-03

Review 5.  [Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection].

Authors:  Valeria Herrera-Lasso Regás; María Teresa Dordal Culla; Ramón Lleonart Bellfill
Journal:  Med Clin (Barc)       Date:  2020-07-09       Impact factor: 1.725

6.  Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials.

Authors:  Zheng Zhang; Yue Yang; Shi-Min Jiang; Wen-Ge Li
Journal:  BMC Nephrol       Date:  2019-08-27       Impact factor: 2.388

7.  Safety and Efficacy Evaluation of Traditional Chinese Medicine (Qingre-Lishi-Yishen Formula) Based on Treatment of Regular Glucocorticoid Combined with Cyclophosphamide Pulse in Children Suffered from Moderately Severe Henoch-Schonlein Purpura Nephritis with Nephrotic Proteinuria.

Authors:  Lirong Fan; Huimin Yan; Xiaofang Zhen; Xiaoming Wu; Jing Hao; Linyi Hou; Lei Han
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-27       Impact factor: 2.629

8.  When and How Is It Possible to Stop Therapy in Patients with Lupus Nephritis: A Narrative Review.

Authors:  Gabriella Moroni; Giulia Frontini; Claudio Ponticelli
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-23       Impact factor: 8.237

9.  Protective Role of Kynurenine 3-Monooxygenase in Allograft Rejection and Tubular Injury in Kidney Transplantation.

Authors:  Randi Lassiter; Todd D Merchen; Xuexiu Fang; Youli Wang
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

Review 10.  Costimulation Blockade in Vascularized Composite Allotransplantation.

Authors:  Dimitrios Giannis; Dimitrios Moris; Linda C Cendales
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.